What’s new

• Q4 revenue hit a record ₹252 cr, with net profit doubling YoY to ₹20.5 cr.
• The new Indore plant reached EBITDA breakeven at just 30% utilization.
• Management guided for at least 15% revenue growth and ~18% EBITDA margin in FY27.

Why it matters

Breakeven at 30% utilization is a hard operational threshold. It means every percentage point of scale increase at Indore adds directly to EBITDA. The formal growth and margin guidance gives FY27 a concrete benchmark.

What we’re watching

• How quickly Indore utilization ramps above the 30% breakeven point through FY27.
• Execution on the new GLP-1 CDMO agreement and Canadian filler in-licensing deal.
• Debt trajectory, guided to stay near ₹400 cr despite the expansion push.

The full read

Gufic Biosciences' best quarter on record produced ₹252 crore in revenue and net profit of ₹20.5 crore, which doubled year-on-year. The operational driver is the new Indore facility reaching EBITDA breakeven at just 30% utilization. That low threshold explains management's confidence in guiding for at least 15% revenue growth and ~18% EBITDA margins in FY27. Every point of utilization above 30% at Indore should translate directly into higher margins. Beyond the facility, the company disclosed a CDMO pact for GLP-1 drugs and an in-licensing deal for Canadian dermal fillers, while shifting its international model toward owning marketing authorisations. Debt stays guided near ₹400 crore. The Indore breakeven number is the key. It turns the growth guidance from an aspiration into a function of a single plant's ramp-up.

Primary source: BSE · NSE